The meeting focused on improving clinical trials management at cancer centers and focused, this year, on “Precision Oncology.” A large shift in the clinical trials industry is shining the spotlight on research ready sites and their ability to identify patients with unique tumor profiles. While these trials can be theory altering for the cancer indication, they are also extremely difficult to complete, due to the extremely small numbers of patients that fit these requirements.
Pharmatech presented on this topic and specifically “Exploring the New Wave of Clinical Trials.” Its chief scientific officer and founder, Dr. Matthew Weiner, discussed how Pharmatech has tackled this momentous challenge of focusing exclusively on the individual patients. Specifically through their AccessPPM program, Pharmatech has addressed this issue head-on and succeeded in enrolling patients into their biomarker identifying database.
“As the landscape of the clinical trials industry changes the challenges faced by clinical research companies are becoming more demanding. Pharmatech is one of the few companies that has addressed these challenges with a dynamic and innovative approach. We were glad to have had the opportunity to share this approach with AACI and its attendees,” said Rob Bohacs, CEO of Pharmatech.
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.
For more information about Pharmatech, please visit www.pharmatech.com.